^
Association details:
Biomarker:EGF expression
Cancer:Tongue Carcinoma
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells

Excerpt:
Our data suggest that the amount of EGF is a determinant of the tumor cell proliferation rate and the response to cetuximab treatment in tongue cancer. Thus, EGF is a potential predictive biomarker of poor cetuximab response and a possible treatment target.
DOI:
10.1111/jop.12310